Examkin

Question

Difficulty: MediumPharmacologic Interventions

An emergency medical services team brings a 58-year-old man to the resuscitation bay due to progressive, profound weakness and an inability to stand. The patient's husband reports that the patient missed his last two hemodialysis appointments because of a local transportation strike. The patient has a known history of end-stage renal disease secondary to hypertensive nephrosclerosis, as well as type 2 diabetes mellitus. Upon arrival, he is lethargic but arousable. Vital signs include a blood pressure of 105/65 mmHg, a heart rate of 42/min, and a respiratory rate of 16/min. An immediate 12-lead electrocardiogram demonstrates marked sinus bradycardia with absent P waves, peaked T waves, and a widened QRS complex. A point-of-care basic metabolic panel reveals a serum potassium concentration of 7.8 mEq/L7.8 \text{ mEq/L}. The clinical team consults nephrology for emergent hemodialysis but determines that temporizing pharmacologic stabilization is required immediately. Arrange the following pharmacologic interventions in the most appropriate sequential order for this patient's acute management.

  1. 1Intravenous calcium gluconate
  2. 2Intravenous regular insulin and 50% dextrose
  3. 3Oral sodium zirconium cyclosilicate

Answer

The correct sequence is: Intravenous calcium gluconate, followed by Intravenous regular insulin and 50% dextrose, followed by Oral sodium zirconium cyclosilicate.
The management of severe hyperkalemia with electrocardiographic changes requires a strict, prioritized approach: stabilize the myocardium, shift potassium intracellularly, and eliminate potassium from the body. Intravenous calcium gluconate is the absolute first priority as it rapidly antagonizes the membrane effects of hyperkalemia, preventing fatal arrhythmias within minutes. Once the myocardium is stabilized, intracellular shifting agents like intravenous regular insulin (co-administered with dextrose to prevent hypoglycemia) are used to temporarily lower serum potassium over 15 to 30 minutes. Finally, agents that physically remove potassium from the body, such as oral sodium zirconium cyclosilicate, are administered; these are given last in the acute sequence because they take hours to exert their effect while definitive therapy (hemodialysis) is arranged.

Step-by-Step Solution

1
Identify the life-threatening emergency.
The patient has severe hyperkalemia (7.8 mEq/L7.8 \text{ mEq/L}) with active cardiac toxicity evidenced by bradycardia, absent P waves, peaked T waves, and a widened QRS complex.
Recognizing electrocardiographic changes in the setting of extreme hyperkalemia dictates an immediate, protocol-driven pharmacologic sequence prior to definitive dialysis.
2
Prioritize myocardial stabilization.
Intravenous calcium gluconate is administered as the absolute first step.
Without immediate membrane stabilization, the patient is at imminent risk of deteriorating into ventricular fibrillation or asystole. Calcium acts within minutes.
3
Initiate intracellular potassium shifting.
Intravenous regular insulin (with dextrose to prevent hypoglycemia) is administered next.
Once the myocardium is protected, shifting potassium into cells temporarily lowers the dangerous extracellular concentration. This bridge therapy takes 15 to 30 minutes to work.
4
Initiate total body potassium elimination.
Oral sodium zirconium cyclosilicate is administered last among these choices.
While definitive removal requires hemodialysis for this anuric patient, gastrointestinal binders contribute to potassium elimination but have a delayed onset of several hours.

Key Concept

Stepwise pharmacologic management of severe hyperkalemia with electrocardiographic changes: 1) Stabilize myocardium, 2) Shift potassium intracellularly, 3) Eliminate potassium.
Estimated Time:1m 30s
Rate this question

Topics

Pharmacologic Interventions

More questions from this topic